Inform Genomics completes first phase in oral mucositis risk prediction study News-Medical.net When commercialized, this product will be available for the hematology oncology stem cell transplant market and will complement the target market of our lead product, OnPART™ for patients with solid tumors." The principal investigator for the study, ... |
